C4 Therapeutics Inc 2025年季度报告

(Mark One) oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ___________________ to ___________________Commission File Number:001-39567________________________________________________ C4 Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) ________________________________________________ (617)231-0700(Registrant’s telephone number, including area code)________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated fileroAccelerated fileroNon-accelerated filerxSmaller reporting companyxEmerging growth companyo If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐Nox As of May1, 2025, the registrant had71,007,083shares of common stock, $0.0001 par value per share, outstanding. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Form 10-Q, including the section entitled “Management’s Discussion and Analysis ofFinancial Condition and Results of Operations,” contains express or implied forward-looking statements that are based on ourmanagement’s belief and assumptions and on information currently available to our management. Although we believe that theexpectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our futureoperational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actualresults, performance, or achievements to be materially different from any future results, performance, or achievements expressed orimplied by these forward-looking statements. Forward-looking statements in this Form 10-Q may include, but are not limited to,statements about: •the initiation, timing, progress, results, safety and efficacy, and cost of our research and development programs and ourcurrent and future preclinical studies and clinical trials, including statements regarding the timing of initiation andcompletion of studies or trials, the period during which the results of the trials will become available, and our researchand development programs;•our ability to obtain funding for our operations necessary to continue or complete further development, manufacturingand commercialization of our product candidates;•our ability to obtain and maintain regulatory approval for any of our current or future product candidates;•the period of time over which we anticipate our existing cash and cash equivalents, and marketable securities will besufficient to fund our operating expenses and capital expenditure requirements;•our ability to identify and develop product candidates for treatment of additional disease indications;•the potential attributes and benefits of our product candidates;•the rate and degree of market acceptance and clinical utility for any product candidates we may develop;•the pricing and reimbursement of our product candidates, if approved, including the possibility for reduced pricing of ourproducts, once approved, if they are later subject to mandatory price negotiation with the Centers for Medicare andMedicaid Services under the Inflation Reduction Act of 2022 or other applicable laws;•the effects of competition with respect to any of our current or future product candidates, as well as innovations bycurrent and future competitors in our industry;•the implementation of our strategic plans for our business, any product candidates we may develop, and our TORPEDOplatform;•theability and willingness of our third-party strategic collaborators to continue research,development,andmanufacturing activ